Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database

Prithviraj Bose, Taylor Schwartz, Jennifer Repp et al. Nov 03, 2025 pp. 6391-6391 10.1182/blood-2025-6391

Abstract Background: Ruxolitinib (RUX) is approved by the US Food and Drug Administration for the treatment of adults with intermediate- or...

Expanding access to haploidentical transplantation : Clinical feasibility of a centralized nationwide distribution model for fresh TCRα/β-depleted grafts in France

Jean-Sebastien Diana, Mony Fahd, Martin Castelle et al. Nov 03, 2025 pp. 5959-5959 10.1182/blood-2025-5959

Abstract Introduction: TCRα/β and CD19 depletion is an in vitro graft engineering method developed for haploidentical hematopoietic stem cel...

SAT1, a novel target of SF3B1 K700E mutant in chronic lymphocytic leukemia, facilitates disease development via regulating T-cell function

Hao Guo, Yongyi Yuan, Siming Zheng et al. Nov 03, 2025 pp. 2098-2098 10.1182/blood-2025-2098

Abstract BackgroundChronic lymphocytic leukemia (CLL) is the most common adult leukemia. Mutations in splicing factor 3b subunit 1 (SF3B1),...

Modeling germline DDX41 and/or CHEK2 mutations using patient-derived bone marrow Organoids

Inci Aydemir, Xu Han, Honghao Bi et al. Nov 03, 2025 pp. 1444-1444 10.1182/blood-2025-1444

Abstract Germline mutations in DDX41 and CHEK2 are recurrently linked to myeloid malignancies, yet their early impact on human hematopoiesis...

Clinical impact of individualized care plans on management of acute pain in the emergency department for children and adults with sickle cell disease

Madhav Vissa, Jessica Liang, Robert Hagar et al. Nov 03, 2025 pp. 2671-2671 10.1182/blood-2025-2671

Abstract Introduction: The American Society of Hematology and National Alliance of Sickle Cell Centers recommend individualized care plans (...

Potential biomarkers and mechanisms in central nervous system involvement of KMT2A rearranged b-ALL: Insights from  Patient-derived xenograft models

Der-Shiun Wang, Jhih-Yu Pan, Yu-Chun Liao et al. Nov 03, 2025 pp. 3256-3256 10.1182/blood-2025-3256

Abstract Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, accounting for nearly 70% o...

The role of BCL-6 in HBV positive diffuse large B-cell lymphoma

Hanying Shen, Linyan Xu, Wei Chen et al. Nov 03, 2025 pp. 7078-7078 10.1182/blood-2025-7078

Abstract In recent years, more and more studies have shown that HBV is closely related to DLBCL and is an important adverse prognostic facto...

Evaluating the july effect on sickle cell crisis hospitalizations: A national inpatient sample analysis from 2016–2022

Abdulmalek Aljafari, Parnita Kesar, Maryam Ali et al. Nov 03, 2025 pp. 7888-7888 10.1182/blood-2025-7888

Abstract Background: Sickle cell disease is a condition seen widely across the nation with acute sickle cell crisis bein...

Single-cell metabolic profiling of post-infusion CD22 and CD19/CD22 CAR T-cells reveals a shift toward amino acid–driven oxphos informing SLC-armored CAR design

Josquin Moraly, Taisuke Kondo, Sooraj Achar et al. Nov 03, 2025 pp. 502-502 10.1182/blood-2025-502

Abstract Chimeric antigen receptor (CAR) T-cell therapies have revolutionized treatment for hematologic malignancies, yet many patients fail...

Revisiting erythroid response in the phase 3 BELIEVE trial of luspatercept in patients with transfusion-dependent β-thalassemia using real-world criteria

Khaled Musallam, Maria Domenica Cappellini, Antonis Kattamis et al. Nov 03, 2025 pp. 1139-1139 10.1182/blood-2025-1139

Abstract Introduction: In the phase 3 randomized, double blind, placebo-controlled BELIEVE trial (NCT02604433) in transfusion-dependent β-th...

PD-1 expression on richter syndrome tumor cells does not provide a growth advantage in murine or patient-derived xenograft models In Vivo

Ivan Negara, Esther Sathya Bama Benjamin, Giulia Felician et al. Nov 03, 2025 pp. 2104-2104 10.1182/blood-2025-2104

Abstract The immune checkpoint receptor Programmed cell death 1 (PD-1) is expressed by the neoplastic B cells in the majority of clonally-re...

Aldehyde dehydrogenase 2 plays a dispensable role in hematopoiesis in response to DNA damage

Liangliang Wu, Jichun Chen, Felix Dingler et al. Nov 03, 2025 pp. 3148-3148 10.1182/blood-2025-3148

Abstract Endogenous formaldehyde is a highly reactive metabolite that can induce DNA damage beyond the capacity of repair pathways, posing a...

Mapping skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) in childhood acute lymphoblastic leukemia survivors using a novel technique oxcest MRI

Ritambhar Burman, Kasturee Chakraborty, Kristy Rodgers et al. Nov 03, 2025 pp. 2579-2579 10.1182/blood-2025-2579

Abstract Introduction. Mitochondrial oxidative phosphorylation (OXPHOS) is the primary energy pathway powering skeletal muscle activity and...

Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11;14)

Shirlene Sim, Adam Bryant, Cecily Forsyth et al. Nov 03, 2025 pp. 249-249 10.1182/blood-2025-249

Abstract Background: Translocation t(11;14) is seen in 20% of multiple myeloma (MM) patients at diagnosis. Cumulative evidence suggests that...

Efficacy and safety of fitusiran prophylaxis in people with haemophilia a or haemophilia B: A systematic review and meta-analysis

Muhammad Burhan, Dua Azim, Taha Ibrahim et al. Nov 03, 2025 pp. 3074-3074 10.1182/blood-2025-3074

Abstract Background: Prophylaxis is the standard of care for people with severe hemophilia A or B to prevent bleeding, but the treatment bur...

Design and characterization of novel albumin-based oxygen carriers as an alternative to whole blood

Alejandra Lorenzen, Hanzhong Li, Gang Huang Nov 03, 2025 pp. 4923-4923 10.1182/blood-2025-4923

Abstract Introduction: Whole blood (WB) transfusion is routinely exercised for resuscitation following hemorrhage, supplementation in anemic...

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles

Shella Saint Fleur-Lominy, Li Chen, Zhuoxin Sun et al. Nov 03, 2025 pp. 290-290 10.1182/blood-2025-290

Abstract Background: Population registries and the Alliance co-operative group database have highlighted racial disparities in AML survival...

Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network

Anna Desalvo, Brittany Ragon, Neel Bhatt et al. Nov 03, 2025 pp. 7913-7913 10.1182/blood-2025-7913

Abstract Background: Dissemination and implementation science (D+I) efforts often begin after clinical trial (CT) efficacy data are availabl...

Impact of episodes of acute chest syndrom on the cardiac remodeling in children and young adults with sicle cell disease.

Luu-Ly Pham, Sylvain LE Jeune, Antonio Morabito et al. Nov 03, 2025 pp. 2972-2972 10.1182/blood-2025-2972

Abstract CONTEXT Cardiac mortality is reported to be the 4th leading cause of death in French children with sickle cell disease (SCD) with a...

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Maria Gabarros-Subira, Sara Torres-Esquius, Helena Pomares et al. Nov 03, 2025 pp. 4275-4275 10.1182/blood-2025-4275

Abstract Introduction After an allogeneic hematopoietic stem cell transplantation (allo-HSCT), a wide range of complications may occur. One...

From society committees to clinical care: Navigating the divide between platelet transfusion thresholds for lumbar puncture across specialties

Adrese Kandahari, Nitin Sekhri, Amir Steinberg Nov 03, 2025 pp. 7906-7906 10.1182/blood-2025-7906

Abstract Institutional generation and adoption of clinical practice guidelines of platelet transfusion thresholds for lumbar puncture (LP) p...

Novel machine learning (ML) and traditional statistical techniques in survival analysis of real-world data for allogeneic hematopoietic cell transplantation (HCT) consolidation in patients with acute lymphoblastic leukemia (ALL)

John Behman, Taiga Nishihori Nov 03, 2025 pp. 6084-6084 10.1182/blood-2025-6084

Abstract IntroductionConsolidative allogeneic hematopoietic cell transplantation (alloHCT) in acute lymphoblastic leukemia (ALL) is a potent...

Divergent trends in high BMI-associated NHL mortality: An analysis of the globalburden of disease database 1990-2021

Amar Lal, Shree Rath, Hyma Polimera Nov 03, 2025 pp. 1835-1835 10.1182/blood-2025-1835

Abstract Introduction: Non-Hodgkin lymphoma (NHL) represents one of the most prevalent hematologic malignancies globally...

Real-World Effectiveness and Resource Utilization of Red Blood Cell Exchange in Adult Sickle Cell Disease: a Nationwide Robust Analysis from 2017-2022

Benedict Amalraj, Anil Ananthaneni, Mariana Marrero Castillo Nov 03, 2025 pp. 7968-7968 10.1182/blood-2025-7968

Abstract Background: Red blood cell exchange (RBCx) is a critical, guideline-recommended therapy for severe, life-threatening complications...

Extended aprepitant in control of delayed emesis during induction chemotherapy for acute myeloid leukaemia – an multicentric, investigator-initiated, open label randomized controlled trial

Sameer Bakhshi, Santhosh Kn, Shuvadeep Ganguly et al. Nov 03, 2025 pp. 1681-1681 10.1182/blood-2025-1681

Abstract IntroductionThe management of chemotherapy induced nausea and vomiting (CINV) during intensive induction chemotherapy for acute mye...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page